Cagrisema (2.5mg+2.5mg)
CagriSema is a combination of Cagrilintide and Semaglutide. By simultaneously targeting amylin and GLP-1 receptors, this co-formulation is studied for its effects on appetite regulation, energy balance, and metabolic homeostasis through complementary biological pathways. Clinical studies, including Phase III trials, have reported substantial reductions in body weight compared to single-agent therapies.
Cagrisema (2.5mg+2.5mg)
Sale!4%
CagriSema is a combination of Cagrilintide and Semaglutide. By simultaneously targeting amylin and GLP-1 receptors, this co-formulation is studied for its effects on appetite regulation, energy balance, and metabolic homeostasis through complementary biological pathways. Clinical studies, including Phase III trials, have reported substantial reductions in body weight compared to single-agent therapies.
$144.00
Buy more, save more!
-
Save 2%
Buy 3, get $2.50 off each
$144.00Per item: $141.50Total price: $424.50 -
Save 3%
Buy 5, get $3.75 off each
$144.00Per item: $140.25Total price: $701.25 -
Save 5%
Buy 10, get $7.50 off each
$144.00Per item: $136.50Total price: $1,365.00
$150.00$144.00
99+% PURITY
All peptides are third-party lab tested.
SECURE PAYMENT
Your payments are secure with our private security network.
FREE SHIPPING
for orders over $250
Description
Additional information
Reviews (0)
CagriSema is a fixed-dose combination of Cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. The combination is designed around the complementary actions of amylin and GLP-1 receptor pathways, which operate through distinct neural mechanisms within the hypothalamus and brainstem regions associated with appetite and satiety regulation.
GLP-1 receptor activity primarily influences appetite through hypothalamic and vagal signalling, while amylin receptor activation acts on the area postrema and nucleus tractus solitarius. This contributes to enhanced appetite suppression and delayed gastric emptying.
CagriSema demonstrated significant reductions in body weight and outperformed previously approved GLP-1 monotherapies.
Research applications include studies focused on:
- Severe obesity
- Metabolic syndrome
- Type 2 diabetes
- Cardiovascular risk management
- Advanced incretin-based combination therapies
| Strength Variation |
|---|
There are no reviews yet.